Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Treatment of Cerebellar Ataxia With Mesenchymal Stem Cells

This study has been completed.
Information provided by (Responsible Party):
Oscar Kuang-Sheng Lee, National Yang Ming University Identifier:
First received: April 10, 2012
Last updated: September 11, 2014
Last verified: September 2014
The study is to investigate the efficacy and safety of allogenous transplantation of adipose-derived mesenchyma stem cells in patients with cerebellar ataxia.

Condition Intervention Phase
Cerebellar Ataxia
Biological: Allogeneic adult adipose-derived mesenchymal stem cells
Phase 1
Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Treatment of Cerebellar Ataxia With Mesenchymal Stem Cells

Resource links provided by NLM:

Further study details as provided by National Yang Ming University:

Primary Outcome Measures:
  • Safety evaluation [ Time Frame: 12 months ]
    Safety evaluate through vital signs, the results of clinical lab tests and adverse events (AEs)

Secondary Outcome Measures:
  • Alterations in SARA score [ Time Frame: 12 months ]
  • Positron emission tomography [ Time Frame: 9 months ]
    18F-FDG used for the assessment of glucose metabolism in the brain

  • Magnetic resonance spectroscopy [ Time Frame: 12 months ]
    NAA/Cr,Cho/Cr,NAA/Cho ratios to reflect neuronal/cerebral white mater integrity

  • Assessment of language and swallowing functions [ Time Frame: 12 months ]
    changes in levels of severity: normal/slight/mild/moderate/severe

  • Evaluation of syncope [ Time Frame: 12 months ]
    Tilt table test

  • Balance test [ Time Frame: 12 months ]

Enrollment: 7
Study Start Date: May 2012
Study Completion Date: January 2014
Primary Completion Date: January 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Mesenchymal stem cells(MSC) treatment
All subjects will receive allogeneic adult adipose-derived mesenchymal stem cells
Biological: Allogeneic adult adipose-derived mesenchymal stem cells
Patients will receive intravenously one dose of 5-7x10^7 cells of allogeneic adipose-derived mesenchymal stem cells


Ages Eligible for Study:   20 Years to 70 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients diagnosed of spinocerebellar ataxia 3 (SCA3) or multiple system atrophy-cerebellar (MSA-C).
  • Subject's SARA score at 10~20 points.
  • Ages between 20~70 years.
  • Signed informed consent from the patient and/or guardian.

Exclusion Criteria:

  • Subjects enrolled in any other cell therapy studies within the past 30 days.
  • Pregnancy test positive.
  • Subjects deemed to be not suitable for the study by the investigator.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01649687

Taipei Veterans General Hospital
Taipei, Taiwan
Sponsors and Collaborators
National Yang Ming University
  More Information

Responsible Party: Oscar Kuang-Sheng Lee, Director of Stem Cell Research Centre, National Yang Ming University Identifier: NCT01649687     History of Changes
Other Study ID Numbers: SB-VGH-201001
Study First Received: April 10, 2012
Last Updated: September 11, 2014

Additional relevant MeSH terms:
Cerebellar Ataxia
Neurologic Manifestations
Nervous System Diseases
Signs and Symptoms
Cerebellar Diseases
Brain Diseases
Central Nervous System Diseases processed this record on May 24, 2017